These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23713616)

  • 1. Favourable changes to the IP and tax systems in the UK for drug development.
    Watson R
    Expert Opin Ther Pat; 2013 Jul; 23(7):773-5. PubMed ID: 23713616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will changes to patent infringements attract drug research in the UK?
    Snodin M
    Expert Opin Ther Pat; 2015; 25(9):949-51. PubMed ID: 25813963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U.S. patent law. Case probes what's fair game in the search for new drugs.
    Kintisch E
    Science; 2005 Apr; 308(5719):174. PubMed ID: 15821048
    [No Abstract]   [Full Text] [Related]  

  • 4. The roles of patents and research and development incentives in biopharmaceutical innovation.
    Grabowski HG; DiMasi JA; Long G
    Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.
    Cockburn I; Long G
    Expert Opin Ther Pat; 2015 Jul; 25(7):739-42. PubMed ID: 25927945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patent tactics in molecular diversity: things that get around, come around (or: there are always exceptions to the rule).
    Bozicevic K
    Mol Divers; 1997-1998; 3(4):235-46. PubMed ID: 9850520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction between intellectual property and drug regulatory systems: global perspectives.
    Madden EA
    IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 11. Patent quality.
    Sklan A
    Pharm Pat Anal; 2014 Jan; 3(1):17-24. PubMed ID: 24354975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amendment to UK Patent Act provides further exception to patent infringement.
    Sklan A
    Pharm Pat Anal; 2014 Jul; 3(4):349. PubMed ID: 25291308
    [No Abstract]   [Full Text] [Related]  

  • 13. Research use exemptions to patent infringement for drug discovery and development in the United States.
    Russo AA; Johnson J
    Cold Spring Harb Perspect Med; 2014 Oct; 5(2):a020933. PubMed ID: 25359549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. India's patent ecosystem - encouraging strong patents or discouraging innovation?
    Harrison C
    Nat Rev Drug Discov; 2013 Oct; 12(10):732-3. PubMed ID: 24080690
    [No Abstract]   [Full Text] [Related]  

  • 15. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
    Grabowski HG; Moe JL
    Cancer Prev Res (Phila); 2008 Jul; 1(2):84-90. PubMed ID: 19138940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Devising a patent strategy to protect the IP of biologics in light of ambiguities, loopholes and pitfalls in the regulatory scheme.
    Hsing BC; Palla SW
    Pharm Pat Anal; 2013 Mar; 2(2):153-5. PubMed ID: 24237017
    [No Abstract]   [Full Text] [Related]  

  • 18. The patents-based pharmaceutical development process: rationale, problems, and potential reforms.
    Barton JH; Emanuel EJ
    JAMA; 2005 Oct; 294(16):2075-82. PubMed ID: 16249422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 20. IP issues facing researchers by Gino D'Oca.
    Almarsson O; Angiolini M; Baell J; Giardina G; Ingham A; Hughes A; Pevarello P; Sindelar R
    Pharm Pat Anal; 2012 May; 1(2):129-35. PubMed ID: 24236778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.